As­traZeneca touts PhI­II event-free sur­vival win with Imfinzi

On the heels of Mer­ck re­port­ing a Phase III win with Keytru­da be­fore and af­ter surgery in non-small cell lung can­cer (NSCLC), As­traZeneca is an­nounc­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.